EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Chemotherapy-induced cognitive impairment and its long-term development in patients with breast cancer: results from the observational CICARO study

Anna Kerkmann iD, Christian Schinke iD, Adam Dordevic, Johannes Kern, Nikola Bangemann, Josefine Finck, Jens-Uwe Blohmer iD, Klemens Ruprecht, Jens C Göpfert, Carolin Otto, Bianca Materne, Matthias Endres iD und 2 weitere

The Oncologist · 06.02.2025 · 30 (2)

DOI: 10.1093/oncolo/oyae268 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift The Oncologist, online erschienen am 14.10.2024. Verfasst von Anna Kerkmann und 13 weiteren Autor:innen. Beteiligte Einrichtung: Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Klinik für Neurologie mit Experi…. Hauptthemen laut MEDLINE: Breast Neoplasms, Chemotherapy-Related Cognitive Impairment, Cognitive Dysfunction. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Center for Stroke Research Berlin, Else-Kröner-Fresenius Stiftung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chemotherapy-induced cognitive impairment (CICI) is a well-recognized side effect of breast cancer treatment. However, prospective long-term evaluations of CICI using standardized neuropsychological tests are scarce. Patients and Methods This prospective longitudinal cohort study investigated cognitive dysfunction and its impact on quality of life and everyday functioning in patients with breast cancer receiving first-line chemotherapy compared to patients with breast cancer without chemotherapy. Assessment occurred prior to chemotherapy, postchemotherapy (median 6 months), and 2-3 years later. We used standardized neuropsychological tests, questionnaires, and scales to assess patients’ quality of life and functioning. Additionally, serum analysis for neurodegenerative markers and autoantibodies was conducted.

Results

We included n = 53 patients. Overall cognitive function declined statistically significantly (P = .046) postchemotherapy compared to control patients, mostly driven by a reduced figural memory (P = .011). Patients who received chemotherapy showed a greater reduction in quality of life (increased fatigue symptoms, P = .023; reduced Karnofsky index, P < .001); however, without a statistically significant effect on cognitive decline. The neurodegenerative markers Neurofilament light chain (NfL) and phosphorylated Neurofilament heavy chain (pNfH) increased statistically significantly (P < .001) postchemotherapy and pNfH correlated with overall cognitive function. After 2-3 years, both cognitive performance and quality of life were comparable between chemotherapy-treated and control patients.

Conclusion

Our findings suggest that chemotherapy statistically significantly contributes to overall cognitive dysfunction in patients with breast cancer, which disappears after 2-3 years, indicating a recovery in both objectively measurable cognitive function and subjective quality of life. Future research should examine larger sample sizes and explore screening indicators, particularly pNfH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsChemotherapy-Related Cognitive ImpairmentCognitive DysfunctionAdultAgedFemaleHumansMiddle AgedLongitudinal StudiesNeuropsychological TestsProspective StudiesQuality of Life

Stichwörter der Autor:innen

CICIbreast cancercognitiveimpairmentneurotoxicityquality of life

Autor:innen und Institutionen

  • Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Klinik für Neurologie mit Experimenteller Neurologie, 10117 Berlin, Germany.
  • Berlin Institute of Health, Charité-Universitätsmedizin Berlin, 10178 Berlin, Germany.
  • Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Klinik für Gynäkologie mit Brustzentrum, 10117 Berlin, Germany.
  • Carl-Thiem-Klinikum Cottbus, Klinik für Senologie und Systemische Gynäkoonkologie mit Brustzentrum, 03048 Cottbus, Germany.
  • NMI Natural and Medical Sciences Institute, University of Tübingen, 72770 Reutlingen, Germany.
  • Charité-Universitätsmedizin Berlin, Institut für Biometrie und Klinische Epidemiologie, 10117 Berlin, Germany.

ORCID-Profile: Anna Kerkmann, Christian Schinke, Jens-Uwe Blohmer, Matthias Endres

Förderung

  • Deutsche Forschungsgemeinschaft
  • Center for Stroke Research Berlin
  • Else-Kröner-Fresenius Stiftung

Zitieren

APA

Kerkmann, A., Schinke, C., Dordevic, A., Kern, J., Bangemann, N., Finck, J., Blohmer, J. U., Ruprecht, K., Göpfert, J. C., Otto, C., Materne, B., Endres, M., Boehmerle, W., & Huehnchen, P. (2025). Chemotherapy-induced cognitive impairment and its long-term development in patients with breast cancer: results from the observational CICARO study. The Oncologist, 30(2). https://doi.org/10.1093/oncolo/oyae268

Vancouver

Kerkmann A, Schinke C, Dordevic A, Kern J, Bangemann N, Finck J, et al. Chemotherapy-induced cognitive impairment and its long-term development in patients with breast cancer: results from the observational CICARO study. The Oncologist. 2025;30(2). doi:10.1093/oncolo/oyae268

BibTeX
@article{Kerkmann2025,
  author = {Kerkmann, Anna and Schinke, Christian and Dordevic, Adam and Kern, Johannes and Bangemann, Nikola and Finck, Josefine and Blohmer, Jens-Uwe and Ruprecht, Klemens and Göpfert, Jens C and Otto, Carolin and Materne, Bianca and Endres, Matthias and Boehmerle, Wolfgang and Huehnchen, Petra},
  title = {Chemotherapy-induced cognitive impairment and its long-term development in patients with breast cancer: results from the observational CICARO study},
  journal = {The Oncologist},
  year = {2025},
  volume = {30},
  number = {2},
  doi = {10.1093/oncolo/oyae268}
}
Kostenlos starten →